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Maximal level-High-level resources or services that may be used in some high-resource countries and/or may be recommended by breast care guidelines that do not adapt to resource constraints but that nonetheless should be considered a lower priority than those resources or services listed in the basic, limited, or enhanced categories on the basis of extreme cost and/or impracticality for broad use in a resource-limited environment; to be useful, maximal-level resources typically depend on the existence and functionality of all lower level resources.
The summary tables presented in this document are an excerpt from the complete guidelines that have been published elsewhere (1) . It is important to note that the table stratification scheme implies incrementally increasing resource allocation at the basic, limited, and enhanced levels. An empty matrix box indicates that additional resource allocation is not mandated beyond those resources required at lower levels. Maximal level resources should not be targeted for implementation in LMCs, even though they may be used in some higher income settings.
The Breast Health Global Initiative (BHGI) is a global health alliance of organizations and individuals. The BHGI strives to develop, implement and study evidence-based, economically feasible, and culturally appropriate guidelines for international breast health and cancer control for low-and middle-income countries to improve breast health outcomes. 
DIAGNOSIS

1:
Breast-conserving surgery can be provided as a limited-level resource but requires breast-conserving radiation therapy. If breast-conserving radiation is unavailable, then patients should be transferred to a higher level facility for postlumpectomy radiation. 2: The use of SLN biopsy requires clinical and laboratory validation of the SLN technique. 3: Systemic chemotherapy requires blood chemistry profile and complete blood count testing for safety. When chemotherapy is available at the basic level, these tests also should be provided. 4: ER testing by IHC is preferred for establishing hormone receptor status and is cost effective when tamoxifen is available. When tamoxifen is available at the basic level, then IHC testing of ER status also should be provided.
5:
If the costs associated with trastuzumab were substantially lower, trastuzumab would be used as a limited-level. In this case, measurement of HER-2/neu overexpression and/or gene amplification would also need to be available at the limited level in order to properly select patients for this highly effective but expensive HER-2/neu targeted biological therapy. 6: Chest wall and regional lymph node irradiation substantially decreases the risk of postmastectomy local recurrence. If available, it should be used as a basic-level resource. 
LEVEL OF AVAILABLE RESOURCES
1:
Chest wall and regional lymph node irradiation substantially decreases the risk of postmastectomy local recurrence. If available, it should be used as a basic-level resource. 2: Systemic chemotherapy requires blood chemistry profile and complete blood count testing for safety. When chemotherapy is available at the basic level, these tests also should be provided. 3: ER testing by IHC is preferred for establishing hormone receptor status and is cost effective when tamoxifen is available. When tamoxifen is available at the basic level, then IHC testing of ER status also should be provided. 4: If the costs associated with trastuzumab were substantially lower, trastuzumab would be used at a limited level. In this case, measurement of HER-2/neu overexpression and/or gene amplification would also need to be available at the limited level in order to properly select patients for this highly effective but expensive HER-2/neu targeted biological therapy.
To find out more about cancer in the Americas and PAHO's work, visit: To find out more about The Breast Health Global Initiative, visit:
